A carregar...
How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation
AIMS: Since 2008, KRAS mutation status in exon 2 has been used to predict response to anti-EGFR therapies. Recent evidence has demonstrated that NRAS status is also predictive of response. Several retrospective ‘extended RAS’ analyses have been performed on clinical trial material. Despite this, are...
Na minha lista:
Publicado no: | J Clin Pathol |
---|---|
Main Authors: | , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BMJ Publishing Group
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5256378/ https://ncbi.nlm.nih.gov/pubmed/27681846 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jclinpath-2016-203822 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|